Physician profile
Michael Greico
NPI 1689102055
$8,485.07
in general payments reported to CMS, 2019-2025
38 companies · $194 in 2025
The $194 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,004 · 2022: $2,372 · 2023: $2,138 · 2024: $1,776 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,108.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,614.62 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,022.24 | 2021-2025 | |
| Novo Nordisk INC | $918.32 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $619.20 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $540.12 | 2021-2024 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $328.55 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $286.29 | 2021-2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $277.11 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $256.43 | 2021-2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $233.18 | 2022-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $232.97 | 2022-2023 | |
| Axsome Therapeutics, INC. | $208.56 | 2023-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $173.40 | 2023-2025 | Voquezna |
| Almatica Pharma LLC | $148.72 | 2022-2024 | Loreev Xr, Sertraline Hcl, Teriparatide |
| Eisai INC. | $147.20 | 2021-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $140.55 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Bausch Health US, LLC | $120.86 | 2022-2024 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $118.81 | 2022 | |
| W. L. Gore & Associates, INC. | $116.02 | 2021 | |
| Amarin Pharma, INC. | $106.78 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $104.06 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Lundbeck LLC | $93.74 | 2022-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $91.46 | 2021-2025 | Zoryve |
| Pfizer INC. | $90.69 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.95 | 2022 | |
| Amgen INC. | $65.03 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Abbott Laboratories | $57.19 | 2022-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $43.95 | 2022-2023 | |
| Intuity Medical INC | $42.89 | 2022 | |
| Ardelyx, INC. | $38.36 | 2024 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $34.29 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.26 | 2021-2022 | |
| Daiichi Sankyo INC. | $28.31 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.31 | 2023 | Xarelto |
| Neurocrine Biosciences, INC. | $16.72 | 2023 | Ingrezza |
| Corcept Therapeutics | $16.68 | 2022 | |
| Linus Health, INC. | $14.75 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Greico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.